{"id":40368,"date":"2021-04-01T07:40:40","date_gmt":"2021-04-01T07:40:40","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40368"},"modified":"2021-11-21T13:51:20","modified_gmt":"2021-11-21T13:51:20","slug":"dual-regeneron-mabs-casirivimab-with-imdevimab-reduce-transmission-interim-results-from-phase-3-study","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40368","title":{"rendered":"Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study"},"content":{"rendered":"

\"\"Simon Collins, HIV i-Base<\/strong><\/p>\n

Another combination of dual nAbs – this time from Regeneron – also reported positive results compared to placebo in reducing the chance of SARS-CoV-2 infection from an interim analysis of a phase 3 study. [1]<\/strong><\/p>\n

This randomised, double-blind, placebo controlled study primarily looked at prophylaxis in household contacts at high risk of SARS-CoV-2, but also included a smaller treatment study in participants who were diagnosed positive at baseline.<\/p>\n

Participants were randomised to either 1200 mg casirivimab\/imdevimab (600 mg of each antibody administered subcutaneously) or to placebo, with interim results presented from the prevention data.<\/p>\n

Significantly fewer participants in the active arm were diagnosed with symptomatic infection: 0\/186 (0%) vs 8\/223 (3.6%); OR: 0.00 (95% CI: 0.00 to 0.69). There were also significantly fewer infections with SARS-CoV-2 PCR levels >1000 copies\/mL: OR: 0.00 (95% CI: 0.00 to 0.37).<\/p>\n

Although the overall rate of SARS-CoV-2 positive infections was reduced, this was not statistically significant: 10\/186 vs 23\/223; OR 0.49 (95% CI: 0.20 to 1.12).<\/p>\n

Placebo recipients having 100-fold greater peak viral load and SARS-CoV-2 became undetectable within a week in the active arm but persisted in 40% of placebo recipients at 3-4 weeks. Statistical significance of both these differences was not reported.<\/p>\n

Earlier results from this combination reported a 0.5 log reduction at day 11. [2]<\/p>\n

References<\/p>\n

    \n
  1. O\u2019Brien MP et al. Casirivimab with imdevimab antibody cocktail for COVID-19 prevention: interim results. CROI 2021, virtual. Late breaker oral abstract 123.
    \nhttps:\/\/www.croiconference.org\/abstract\/casirivimab-with-imdevimab-antibody-cocktail-for-covid-19-prevention-interim-results\/<\/a> (abstract and webcast)<\/li>\n
  2. Two different dual antibody treatments each reduce SARS-CoV-2 viral load by >0.5 log. HTB (22 January 2021).
    \n    https:\/\/i-base.info\/htb\/39718<\/a><\/li>\n<\/ol>\n

    This report was first published on 19 March 2021.<\/em><\/p>\n\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Another combination of dual nAbs – this time from Regeneron – also reported positive results compared to placebo in reducing the chance of SARS-CoV-2 infection from an interim analysis of a phase 3 study. [1] This …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,283,278],"tags":[307],"class_list":["post-40368","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-covid-19-investigational-drugs","category-covid-19","tag-croi-2021-virtual"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40368"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40368\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}